Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 11/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 5/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 3/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 3/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.40 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL8138712 | 0.88 | MAPK8 (0.53) | MAPK8MAPK9MAPK10KCNH2GABRA1 | |
| SCHEMBL13106420 | 0.85 | MAPK8 (0.56) | MAPK8MAPK9MAPK10KCNH2GABRA1 | |
| SCHEMBL16881243 | 0.82 | MAPK8 (0.49) | MAPK8MAPK9MAPK10GABRA1GABRG2 | |
| SCHEMBL15898846 | 0.82 | GABRA1 (0.48) | MAPK8MAPK9MAPK10GABRA1GABRG2 | |
| Ammonia Solution, Strong SCHEMBL905873 | 0.81 | MAPK8 (0.44) | MAPK8MAPK9MAPK10KCNH2GABRA1 | |
| SCHEMBL3347656 | 0.79 | MAPT (0.41) | MAPK8MAPK9MAPK10KCNH2KDM4E | |
| Ammonia Solution, Strong SCHEMBL905834 | 0.79 | KDM4E (0.45) | LMNARAB9AKDM4EMAPT | |
| SCHEMBL9323969 | 0.76 | AKR1B1 (0.51) | MAPK8MAPK9MAPK10 | |
| SCHEMBL905751 | 0.76 | HTR2A (0.43) | MAPK8MAPK9MAPK10PIM1 | |
| SCHEMBL7073025 | 0.75 | GPR3 (0.43) | LMNARAB9AKDM4EMAPTCASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2000012482-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| CN-1780612-B | Treatment of incontinence with 5HT2C agonists. | PFIZER | 2010-12-01 | — | — | CN | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| CN-1780612-A | Treatment of incontinence with 5HT2C agonists. | PFIZER (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| WO-2000012482-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | MAPK8 3756/4885MAPK9 4392/4885MAPK10 4129/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | MAPK8 3756/4885MAPK9 4392/4885MAPK10 4129/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | MAPK8 3756/4885MAPK9 4392/4885MAPK10 4129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.